News & Events about Beam Therapeutics Inc.
Beam Therapeutics Inc. (NASDAQ:BEAM Get Rating) CFO Terry-Ann Burrell sold 47,195 shares of the companys stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $45.14, for a total value of $2,130,382.30. Following the transaction, the chief ...
Beam Therapeutics Inc. (NASDAQ:BEAM Get Rating) insider Giuseppe Ciaramella sold 51,015 shares of the firms stock in a transaction on Monday, December 12th. The shares were sold at an average price of $42.70, for a total value of $2,178,340.50. Following the completion of the sale, the insider now ...
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and ExpositionCAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base ...
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New...